Pay in 4 interest-free payments of $6.51 Learn more
Ships within 48 hours · Estimated delivery Aug 27 - Sep 1
Geographic Availability Available in all 50 states (eligibility for compounded meds varies by state) Clinical Oversight and Safety Licensed providers review each case and personalize the dose
Tremfya (guselkumab) Disease area(s): Immunology Manufacturer(s): Johnson & Johnson 2024 Sales (USD): $3.67 billion Why it sold so well: J&Js IL-23 inhibitor Tremfya experienced significant sales growth last year with $3.67 billion in total sales, an increase of 16.6% from 2023
Biomaterials 35 , 46884698 (2014)
( B ) A diagram showing the binding sites of ELT-3 and PQM-1 in tig-2 promoter
US$ 28.28
:max_bytes(150000):strip_icc()/glycine-overview-4583816-FINAL-1-1-075890ee128542f1bd3cfc5f83310d50.png)
US$ 25.33
US$ 29.48
US$ 25.19
US$ 24.66
US$ 23.82
US$ 25.29
